Industry Contributions
by Our Founders
See PRN’s published contributions to clinical research study methods.
Stewart WC, Nelson LA, Stewart JA. What Data Sources Do Ophthalmologists Trust? Evid Based Med. 2017; 22: 205-207.
DeMill DL, Wirotsko B, Stewart JA, Nelson LA, Stewart WC. Single- versus double-masking in glaucoma clinical trials. Perpspect Clin Res 2016;7:147-148.
Stewart WC, Stewart JA, Nelson LA. Glaucoma clinical trial design: a review of the literature. Perspect Clin Res 2014;5:108-14.
Stewart WC, Limtong AC, Magrath GN, Rembold JC, Nelson LA, Stewart JA. Lower limits of intraocular pressure in glaucoma clinical trials. J Glaucoma 2014;23:e105-7.
Stewart WC, Stewart JA, Nelson LA, Kruft B. Mean standard deviations for common glaucoma treatments. Acta Ophthalmol Scan 2009;87:112-4.
Stewart WC, Jenkins JN. Predictive value of the efficacy of glaucoma medications in regulatory trials: Phase I-III to post-marketing studies. Eye 2008;22:985-8.
Stewart WC, Geiger AC, Jenkins JN. The benefit of repeated intraocular pressure measurements in clinical trials. Arch Ophthalmol 2004;122:936-7.
Stewart WC, Holmes KT, Johnson MA. Washout periods for brimonidine 0.2% and latanoprost 0.005%. Am J Ophthalmol 2001;131:798-9.
DeMill DL, Wirostko BM, Nelson LA, Stewart WC. Upper limits of intraocular pressure in glaucoma clinical trials. Am J Ophthalmol 2001;131:798-9..
Stewart WC, DeMill DL, Wirostko BW, Nelson LA, Stewart JA. A review of pigment dispersion and exfoliation glaucoma diagnosis on intraocular pressure in clinical trials evaluating primary open-angle glaucoma and ocular hypertension. J Glaucoma 2013;22:506-509.
DeMill DL, Wirostko BM, Nelson LA, Stewart JA, Stewart WC. Average eye versus highest intraocular pressure analyses in glaucoma clinical trials. Ophthalmic Res 2013;49:49-51.
Sharpe RA, Nelson LA, Stewart JA, Stewart WC. The placebo effect in early phase glaucoma clinical trials. Curr Eye Res 2015;40:653-6.
Sharpe RA, Nelson LA, Stewart JA, Stewart WC. Intraocular pressure efficacy of glaucoma medications versus placebo in Phase II compared to later phase trials. Br J Ophthalmol 2013;97:121-5.
Sharpe RA, Davidson J, Nelson LA, Stewart JA, Stewart WC. Techniques to reduce the placebo effect in glaucoma clinical trials. Ophthalmic Res 2015;54:1-3.
Stewart WC, Magrath GN III, Demos CM, Nelson LA, Stewart JA. Predictive value of the efficacy of glaucoma medications in animal models: Pre-clinical to regulatory studies. Br J Ophthalmol 2011;95:1355-60.
Stewart WC, Demos CM, Turner M, Stewart JA. Factors associated with site requirement for glaucoma clinical trials. Graefes Arch Clin Exp Ophthalmol 2010;248:1527-8.
Stewart WC, Demos CM, Turner MK, Stewart JA. Risk factors for subject withdrawals in clinical trials evaluating glaucoma medications. Graefes Arch Clin Exp Ophthalmol 2010;248:1007-12.
Stewart WC, Robin AL, Sharpe ED, Hennessy A, Stewart JA. Glaucoma clinical trials. Ophthalmology 2010;117;397.
Stewart WC, Jackson AL, Jenkins JN. Dropout rates for intent-to-treat and per protocol analyses. Am J Ophthalmol 2004;137:639-45.
Stewart WC, Jackson AL, Jenkins JN. Can patients guess their intraocular pressure? Am J Ophthalmol 2004;137:350-1.
Stewart WC, Demos CM, Turner M, Stewart JA. Serious adverse event reporting. Ophthalmology 2009;116:2485.
Kruft B, Nelson LA, Stewart JA, Stewart WC. Adverse event reporting in ophthalmic clinical trials. Ophthalmology 2007;114:1420.